Supreme Court Report

Supreme Court of the United States · Official docket →

Biogen International GmbH, et al. v. Mylan Pharmaceuticals Inc.

Paid petition · United States Court of Appeals for the Federal Circuit, No. 2020-1933 · judgment November 30, 2021


Certiorari denied · October 3, 2022
Pre-decision estimate: 5% cert probability (95% interval 3%–9%)

Before the decision, modestly above the 4.1% base rate. The model weighted this up for counsel who has won certiorari before, a dissent in the court below (flagged in the petition), and a Federal Circuit decision below, and down for a business respondent.

Question presented

J. MICHAEL JAKES JAMES B. MONROE PAUL W. BROWNING JASON L. ROMRELL FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP 901 New York Ave., NW Washington, DC 20001 (202) 408-4000

Counsel of record

For petitioner
Seth P. Waxman
Wilmer Cutler Pickering Hale and Dorr LLP

For respondent
Nathan Kip Kelley
Perkins Coie LLP

Case

Conference history
Distributed for 1 conference

Amicus briefs
3 cert-stage

Proceedings

  1. Oct 03 2022
    Petition DENIED.
  2. Aug 31 2022
    DISTRIBUTED for Conference of 9/28/2022.
  3. Aug 30 2022
    Reply of petitioners Biogen International GmbH and Biogen MA Inc. filed. (Distributed)
  4. Aug 15 2022
    Brief of respondent Mylan Pharmaceuticals Inc. in opposition filed.
  5. Jul 15 2022
    Brief amici curiae of Pharmaceutical Research and Manufacturers of America, et al.
  6. Jul 14 2022
    Brief amicus curiae of New England Legal Foundation filed.
  7. Jul 11 2022
    Brief amicus curiae of Chemistry and the Law Division of the American Chemical Society filed.
  8. Jul 01 2022
    Motion to extend the time to file a response is granted and the time is extended to and including August 15, 2022.
  9. Jun 30 2022
    Motion to extend the time to file a response from July 15, 2022 to August 15, 2022, submitted to The Clerk.
  10. Jun 14 2022
    Petition for a writ of certiorari filed. (Response due July 15, 2022)